Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Congress for Shoulder and Elbow Surgery (ICSES) in Vancouver from September 22-25. Surgeons are invited to visit the Smith+Nephew booth during ICSES to learn more about the following technologies:
TENDON SEAM Rotator Cuff Repair System
Recently acquired by Smith+Nephew, the TENDON SEAM System is a unique rotator cuff repair solution that offers superior load sharing designed to maximize repair strength throughout the healing period.1-4,*,** The construct features multiple tightly spaced 2x10mm anchors connected by a continuous stitch designed to distribute forces across the repaired tendon with a seam of fixation perpendicular to the direction of load. Biomechanical testing demonstrates a 2X increase in repair strength and 10X decrease in gap formation compared with traditional techniques, 1-4,* with encouraging early clinical outcomes.5 View the TENDON SEAM Rotator Cuff Repair System webpage here.
REGENETEN◊ Bioinductive Implant
With more than 250,000 procedures6 completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact for rotator cuff repair, demonstrating reduced risk of retear*** and benefits for patient recovery.7-9,± The bioinductive implant, with highly purified, highly porous, highly oriented collagen fibers, supports the body’s natural healing response to facilitate the formation of new tissue.10-14 A study published earlier this year concluded that early recovery time was halved following isolated use of the REGENETEN Implant for partial thickness rotator cuff tears when compared with a traditional suture anchor repair.15,±,‡ Patients also enjoyed a better shoulder-related quality of life at 6 weeks and 3 months.15,±,‡ Learn more about the REGENETEN Bioinductive Implant in partial-thickness tears, including the recent 4-star recommendation from AAOS for bioinductive implants, by visiting the webpage here.
Q-FIX◊ KNOTLESS 2.8 All-Suture Anchor – Launching at ICSES!
The Q-FIX KNOTLESS 2.8 All-Suture Anchor is designed for the shoulder surgeon that wants best-in-class reliability,16,† but in a knotless construct which allows fine-tuned tensioning of soft tissue. The Q-FIX KNOTLESS 2.8 Anchor has the versatility to meet the needs of various surgical procedures, tissue/bone quality, or surgeon preference, in different anatomies and surgical procedures. To learn more about the Q-FIX KNOTLESS family of all-suture anchors, please see the product brochure here.
Differentiated shoulder arthroplasty technology for personalized care
CORIOGRAPH◊ Pre-Op Planning and Modeling Services and CORI◊ SHOULDER Handheld Robotics Arthroplasty with the AETOS◊ Shoulder System offer a complete robotic procedure supporting handheld robotic execution of the humerus and glenoid, across both anatomic and reverse procedures.
Skill amplified. The freedom of handheld robotics.
The best technology works naturally with surgical skill. The CORI XT Handheld Robotics Platform seamlessly integrates with current surgical workflows and was designed with a footprint tailored to the unique needs of hospitals and ambulatory surgical suite settings.17 It has a leaner platform configuration which moves easily between rooms.18,¥
For more information about CORIOGRAPH Pre-Op Planning Services and CORI SHOULDER Handheld Robotics Arthroplasty, please visit the webpage here. If you will be attending ICSES, be sure to join our CORI SHOULDER Handheld Robotics Arthroplasty evening event on Sept 22. Click here to register: https://lnkd.in/eM5CJ3QW. Spaces are limited.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.